Minims Prednisolondinatriumfosfaat Bausch Health Ireland (Prednisolone Sodium Phosphate)

The drug penetrates ocular tissues and binds to intracellular glucocorticoid receptors. This complex inhibits phospholipase A2 and suppresses the production of inflammatory mediators such as prostaglandins and cytokines, thereby decreasing vascular permeability and inflammatory cell infiltration in the eye.

The dosing regimen for Minims Prednisolondinatriumfosfaat is determined by the prescribing clinician based on the specific indication, severity of inflammation and patient response. The prescriber will provide instructions on the number of drops, frequency and duration of therapy.

Safety data for prednisolone sodium phosphate in pregnancy and lactation are limited. The decision to use the product during pregnancy or while nursing should be made by the healthcare professional after weighing potential benefits against possible risks to the mother and infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Prednisolone sodium phosphate and dexamethasone are both potent glucocorticoids for ocular use. Prednisolone generally offers a slightly broader anti‑inflammatory spectrum, while dexamethasone may have a longer ocular residence time. Choice between them depends on the clinician’s assessment of efficacy, tolerability and patient‑specific factors.

The ophthalmic solution should be stored at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and discard any remaining product after the labeled period once opened.

The drops are instilled directly into the conjunctival sac of the affected eye(s) as instructed by the prescriber. Patients should wash their hands, avoid touching the tip of the bottle to the eye or any surface, and gently close the eye after administration to allow even distribution.

Serious adverse events include secondary ocular infection, cataract formation, increased intra‑ocular pressure leading to glaucoma, and rare systemic effects such as adrenal suppression. Patients should report any sudden vision changes, eye pain, redness or signs of infection to their healthcare provider promptly.

The product is contraindicated in patients with known hypersensitivity to prednisolone sodium phosphate or any excipients, and in those with active viral eye infections such as herpes simplex keratitis. Caution is also advised for individuals with uncontrolled glaucoma or a history of steroid‑induced ocular hypertension.